Who is spironolactone used for in androgen-related hair thinning, and who should avoid it?

Spironolactone is a medication that was originally developed and approved to treat conditions such as high blood pressure, heart failure, and fluid retention. Over time, clinicians observed that it also affected hormones known as androgens, which are involved in certain types of hair thinning and hair loss. This observation led to its off-label use in dermatology, particularly for people experiencing androgen-related hair loss.Off-label use means that a medication is prescribed for a purpose not specifically listed in its original regulatory approval.

Hair thinning linked to androgens most commonly appears as female pattern hair loss, a condition characterized by gradual thinning over the crown and widening of the part, while usually preserving the frontal hairline. In some cases, spironolactone may be helpful because it reduces the effect of androgens on hair follicles. However, this does not mean it is appropriate or safe for everyone. Understanding who can safely use spironolactone requires careful consideration of biology, medical history, and the evidence behind its use.

Understanding androgen-related hair loss in simple terms

Androgens are hormones present in all people, although typically at higher levels in males. One androgen in particular, dihydrotestosterone, plays a central role in androgen-related hair loss. In susceptible hair follicles, dihydrotestosterone binds to receptors and gradually shortens the growth phase of hair. Over time, hairs become thinner, shorter, and eventually may stop growing.

Spironolactone works by blocking androgen receptors and reducing the production and activity of these hormones. By limiting the ability of androgens to affect hair follicles, spironolactone may slow hair thinning and, in some cases, allow partial regrowth. This mechanism explains why its use is mainly considered in people whose hair loss has a hormonal component rather than hair loss caused by scarring, autoimmune disease, or nutritional deficiencies.

Who spironolactone is most often studied in

Most of the published evidence on spironolactone for hair thinning comes from adult women with androgen-related hair loss. Women with signs of androgen excess, such as acne, excess facial or body hair, or irregular menstrual cycles, are often considered suitable candidates. In these individuals, spironolactone addresses an underlying hormonal influence rather than acting only on the hair follicle itself.

Women diagnosed with conditions such as polycystic ovary syndrome are frequently included in studies of spironolactone for hair loss. Polycystic ovary syndrome is a hormonal condition in which androgen levels may be elevated or hair follicles may be more sensitive to androgens.Whether spironolactone works better for hair thinning in women with polycystic ovary syndrome than in other women has not been shown in the studies cited here.

Postmenopausal women may also be considered, particularly when hair thinning worsens after menopause. Although overall hormone levels decline after menopause, the balance between estrogen and androgens shifts in a way that can favor androgen effects on hair follicles. Spironolactone may help counteract this shift, although expectations should remain realistic, as the medication tends to slow progression rather than restore youthful hair density.

Why spironolactone is generally not considered safe for men

Although spironolactone affects the same androgen pathways involved in male pattern hair loss, it is rarely prescribed to men for this purpose. This is because blocking androgen activity in men can lead to unwanted systemic effects, including breast tissue development (the US label lists gynecomastia, and says the risk rises with dose), reduced libido, and potential fertility issues. These effects are directly related to the role androgens play in male physiology.

Oral spironolactone is rarely used in men for hair loss; treatments approved for male pattern hair loss are generally used instead. This distinction highlights the importance of biological differences in determining who can safely use this medication.

Safety considerations that determine eligibility

Spironolactone affects fluid balance and potassium levels in the body. The US label lists high blood potassium (hyperkalemia), Addison's disease and use with eplerenone as contraindications, and warns that kidney impairment or other potassium-raising drugs increase the risk of hyperkalemia. The label advises checking blood potassium within one week of starting and regularly after that, and monitoring kidney function (DailyMed, Aldactone).

The US label warns that spironolactone may affect sexual development of a male fetus (animal studies showed feminization of male fetuses), so it is avoided in pregnancy. Women who could become pregnant are usually advised to use reliable contraception while taking it (DailyMed, Aldactone).

Interactions with other medications also influence safety. Drugs that increase potassium levels or affect kidney function can amplify the risks associated with spironolactone. This is why medical evaluation and ongoing supervision are essential components of safe use.

What research really says about effectiveness and safety

Clinical studies on spironolactone for hair loss are mostly observational rather than large randomized trials. One influential open study published in 2005 treated 80 women with female pattern hair loss with oral spironolactone (40 women) or cyproterone acetate (40 women) for at least twelve months. Clinicians who did not know the treatment rated standardized scalp photographs. With both drugs combined, 44% had regrowth, 44% had no clear change and 12% continued to lose hair (Sinclair et al. 2005). The study had no placebo group, which limits the strength of the conclusions.

A 2023 systematic review and meta-analysis (Aleissa, Cureus) pooled studies of oral spironolactone in female pattern hair loss. It reported improvement in 56.6% of patients and no or only modest improvement in 37.8%. The author noted significant variability between studies in design, dose and outcome measures, which makes direct comparison difficult.

In a 2025 placebo-controlled pilot trial, 37.5% of women taking spironolactone 100 mg reported menstrual irregularity, significantly more than on placebo (Werachattawatchai et al. 2025). Other reported effects include breast tenderness and, per the US label, high blood potassium.

How results are evaluated and why expectations matter

Researchers typically assess spironolactone’s effect on hair using standardized scalp photographs, hair density counts, and patient questionnaires. These methods help capture both objective changes and subjective satisfaction. It is important to explain that hair growth cycles are slow, and meaningful evaluation usually requires at least six to twelve months of continuous treatment.

In the 2005 open study, as many women had no clear change (44%) as had regrowth (44%), which is why spironolactone is often described as better at slowing thinning than at producing dramatic regrowth. This distinction is crucial for patients deciding whether the treatment aligns with their goals and expectations.

Limitations and criticisms of existing research

Despite decades of clinical use, high-quality randomized controlled trials on spironolactone for hair loss remain limited. Many studies involve small sample sizes and lack long-term follow-up beyond one or two years. Additionally, most research focuses on women of similar age groups, reducing the generalizability of findings.

Another criticism is the reliance on subjective outcome measures. While patient perception is important, it can be influenced by expectations and concurrent treatments such as topical minoxidil. Researchers frequently acknowledge these limitations and call for more rigorous trials.

Answering the central question clearly

Spironolactone for hair thinning and androgen-related hair loss is studied mainly in adult women with evidence of hormonal involvement, particularly those with conditions such as female pattern hair loss or polycystic ovary syndrome. Its use is off-label and needs a prescriber. The US label calls for potassium monitoring, and it is avoided in pregnancy. Researchers describe the current evidence as limited and call for more robust studies.

Research and regulatory context

Regulatory agencies such as the United States Food and Drug Administration recognize spironolactone as an approved medication for cardiovascular and hormonal conditions, but not specifically for hair loss. Its dermatologic use is based on peer-reviewed research and clinical consensus rather than formal approval for this indication. This distinction reinforces the importance of informed decision-making guided by qualified healthcare professionals.

References

Aleissa, M., et al. (2023). The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: A systematic review and meta-analysis. PubMed. https://pubmed.ncbi.nlm.nih.gov/37719557/

Werachattawatchai, P., Khunkhet, S., Harnchoowong, S., & Lertphanichkul, C. (2025). Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: Randomized controlled pilot study. PubMed. https://pubmed.ncbi.nlm.nih.gov/40978669/

Sinclair, R., Wewerinke, M., & Jolley, D. (2005). Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology, 152(3), 466–473. https://pubmed.ncbi.nlm.nih.gov/15787815/

Scheinfeld, N. (2008). A review of hormonal therapy for female pattern (androgenic) alopecia. PubMed. https://pubmed.ncbi.nlm.nih.gov/18627703/

Salavastru, C. M., Fritz, K., & Tiplica, G. S. (2013). Spironolactone in dermatological treatment: On- and off-label indications. Hautarzt, 64(10), 762–767. PubMed. https://pubmed.ncbi.nlm.nih.gov/24150826/

Pfizer. ALDACTONE (spironolactone) tablets: prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc